In a Phase IIa trial (CARDINAL-HF), the PDE9A inhibitor CRD-740, was administered to patients with HFrEF, characterized by reduced left ventricular ejection fraction but without systematic assessment of right ventricular function. This evidence concerns the gene PDE9A and hydrops fetalis.